Interview with Kalman Petro, Managing Director, Actavis BV
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Address: Minervum 7061, 4817 ZK, Breda,Netherlands
Tel: 076-5732500
Web: http://www.amgen.nl/dutch/index.html
Sinds 1997 levert Amgen vanuit Breda haar producten door heel Europa en aan een groeiend aantal landen in andere delen van de wereld. We verpakken medicijnen landenspecifiek, slaan ze tijdelijk op en verschepen uiteindelijk naar meer dan 50 landen.
Voor Amgen Europe B.V. geldt: “Elke patiënt, telkens weer”. Hiermee bedoelen we dat we ernaar streven om onze producten altijd beschikbaar te hebben op de juiste plaats en op de juiste tijd voor de behandeling van de patiënt. Vanuit Breda distribueren we zowel geregistreerde producten als producten die gebruikt worden in klinisch onderzoek. Breda is ook de vestigingsplaats van twee onderdelen van de Global Supply Chain organisatie verantwoordelijk voor Europa, Afrika en Australië/Nieuw-Zeeland. Daarnaast is Amgen Breda het internationale centrum buiten de Verenigde Staten voor enkele andere functies, zoals Quality & Regulatory Compliance, Information Systems en Financial Shared Services.
Circa 500 gemotiveerde mensen werken samen in hun streven naar perfectie in hun werkzaamheden, met als uiteindelijke doel het verbeteren van mensenlevens.
Amgen has marketed various key breakthrough products including Aranesp, Neulasta, Neupogen, Mimpara en Nplate all of which have made a vital contribution to patients’ welfare. Amgen’s future aims will also remain centred on finding innovative solutions for patients. This is why Amgen continues to develop new products for syndromes where treatment options are insufficient.
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
As the chairman of a consortium that has been working towards both medical and technological progress in the region, how have you seen this progress taking place in the Netherlands…
Deloitte is renowned for its strong network of international expertise. Yet every market has its own particularities… Having spent 16 years with the company, in your opinion, what is it…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
See our Cookie Privacy Policy Here
